Read by QxMD icon Read

Gastroenteropancreatic neuroendocrine tumor

Antongiulio Faggiano, Silvana Di Maio, Carmela Mocerino, Margaret Ottaviano, Chiara De Divitiis, Valentina Guarnotta, Pasquale Dolce, Roberta Modica, Ivana Puliafito, Lucia Tozzi, Antonella Di Sarno, Silvana Leo, Ferdinando Riccardi, Giovannella Palmieri, Salvatore Tafuto, Antonella Bianco, Giuseppe Badalamenti, Annamaria Colao
PURPOSE: Many different treatments are suggested by guidelines to treat grade 1-2 (G1-G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the main therapeutic sequences in G1-G2 NET. METHODS: A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in NET. Median progression-free survival (PFS) was compared between therapeutic sequences, as well as the number and grade of side effects and the rate of dose reduction/treatment discontinuation...
March 14, 2019: Endocrine
Rebekka Mai, Daniel Kaemmerer, Tina Träger, Elisa Neubauer, Jörg Sänger, Richard P Baum, Stefan Schulz, Amelie Lupp
Somatostatin receptors (SST), especially SST2A, are known for their overexpression in well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). The chemokine receptor CXCR4, in contrast, is considered to be present mainly in highly proliferative and advanced tumors. However, comprehensive data are still lacking on potential differences in SST or CXCR4 expression pattern in GEP-NEN in dependence on the place of origin. Overall, 412 samples from 165 GEP-NEN patients, comprising both primary tumors (PT) and metastases (MTS), originating from different parts of the gastrointestinal tract or the pancreas were evaluated for SST and CXCR4 expression by means of immunohistochemistry using monoclonal antibodies...
March 13, 2019: Scientific Reports
Anna Malczewska, Magdalena Witkowska, Karolina Makulik, Agnes Bocian, Agata Walter, Joanna Pilch-Kowalczyk, Wojciech Zajęcki, Lisa Bodei, Kjell E Oberg, Beata Kos-Kudła
INTRODUCTION: Current monoanalyte biomarkers are ineffective in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). NETest, a novel multianalyte signature, provides molecular information relevant to disease biology. AIM(S): Independently validate NETest to diagnose GEP-NETs and identify progression in a tertiary referral center. MATERIALS AND METHODS: Cohorts: 67 pancreatic NET (PNETs), 44 small intestine NETs (SINETs), 63 controls. Well-differentiated (WD): PNETs, n=62, SINETs, all (n=44)...
March 1, 2019: Endocrine Connections
Amit Tirosh, J Keith Killian, Yuelin Jack Zhu, David Petersen, Jennifer Walling, Ronit Mor-Cohen, Vladimir Neychev, Holly Stevenson, Xavier M Keutgen, Dhaval Patel, Naris Nilubol, Paul Meltzer, Electron Kebebew
Purpose to report the rate of candidate actionable somatic mutations in patients with locally advanced and metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET) and of other genetic alterations that may be associated with tumorigenesis Methods A phase II mutation targeted therapy trial was conducted in patients with advanced well differentiated G1/G2 GEP-NETs. Mutations found in mTOR pathway associated genes, led to treatment with the mTOR inhibitor everolimus, and were defined as actionable. Tumor DNA from GEP-NETs were sequenced and compared with germline DNA, using the OncoVar-NET assay, designed for hybrid capture sequencing of 500 tumor suppressor genes and oncogenes...
March 13, 2019: Endocrine Practice
Patience Green, Electron Kebebew
BACKGROUND: We sought to assess participation of underrepresented minorities with endocrine neoplasms in clinical trials conducted in the National Cancer Institute's (NCI) Intramural Research Program. METHODS: We performed a retrospective analysis of patients enrolled in Endocrine Oncology Branch (EOB) clinical trials, comparing demographics to regional and national demographics. We compared specific endocrine cancer patient data to data from NCI's Surveillance, Epidemiology, and End Results (SEER) program...
February 14, 2019: American Journal of Surgery
Enrique Grande, Ángel Díaz, Carlos López, Javier Munarriz, Juan-José Reina, Ruth Vera, Beatriz Bernárdez, Javier Aller, Jaume Capdevila, Rocio Garcia-Carbonero, Paula Jimenez Fonseca, Marta Trapero-Bertran
Background: Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce. Methods: A systematic review on the economic impact of GEP-NETs was carried out using four databases: EMBASE, PubMed , the National Health Service Economic Evaluation Database and Cochrane review ...
2019: Therapeutic Advances in Endocrinology and Metabolism
Jiangyuan Yu, Nan Li, Jie Li, Ming Lu, Jeffrey P Leal, Huangying Tan, Hua Su, Yang Fan, Yan Zhang, Wei Zhao, Hua Zhu, Martin G Pomper, Yun Zhou, Zhi Yang
PURPOSE: Objectives of the study are to analyze the correlation between [68 Ga]DOTATATE positron emission tomography (PET)/X-ray computed tomography (CT) measurements and various biological characteristics of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), and to determine optimal cutoff value of SUVmax (standard uptake value) to differentiate neuroendocrine tumors (NETs) and neuroendocrine cancers (NECs). PROCEDURES: Of the GEP-NEN cases (73 males, 53 females; age 18-77 years) with pathologically proven primary and/or metastatic lesions, 126 were studied...
February 22, 2019: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
Ömer Komaç, Göksel Bengi, Özgül Sağol, Mesut Akarsu
BACKGROUND: Long non-coding RNAs (lncRNAs) are a kind of single-stranded RNA of more than 200 nucleotides in length and have no protein-coding function. Amounting studies have indicated that lncRNAs could play a vital role in the initiation and development of cancers, including gastric cancer (GC). Considering the crucial functions of lncRNAs, the identification and exploration of novel lncRNAs in GC is necessary. AIM: To identify independent prognostic markers for the whole gastroenteropancreatic neuroendocrine tumor (GEP-NET) group...
February 15, 2019: World Journal of Gastrointestinal Oncology
Amr Mohamed, Jonathan R Strosberg
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are relatively rare neoplasms, characterized by a propensity to secrete hormones which cause distinct clinical syndromes. During the past decade, the systemic treatment landscape has improved significantly: new options include everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), sunitinib, an angiogenesis inhibitor, and cytotoxic regimens such as capecitabine and temozolomide. Moreover, the recent approval of the radiolabeled somatostatin analog 177 Lutetium(Lu)-dotatate has had a significant impact on management of neuroendocrine malignancies...
February 8, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Madhav Prasad Yadav, Sanjana Ballal, Chandrasekhar Bal
BACKGROUND: The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of combined capecitabine and 177 Lu-DOTATATE in malignant PGL patients. METHODS: In this retrospective, single-institutional, single-arm, observational study, data of consecutive advanced stage PGL patients treated with concomitant 177 Lu-DOTATATE-capecitabine therapy, between July 2009 and March 2017, were collected and analyzed...
February 6, 2019: EJNMMI Research
Yelda Dere, Osman Ozkaraca, Gurcan Cetin, Ozcan Dere
OBJECTIVE: To design an application which can calculate Ki67 and compare its results with the traditional method in gastroenteropancreatic (GEP)-neuroendocrine tumors (NETs). STUDY DESIGN: Descriptive analytical study. PLACE AND DURATION OF STUDY: Faculties of Medicine and Technology of Mugla Sitki Kocman University between January 2015 to January 2016. METHODOLOGY: A new analyser for detecting the exact percentage of positive cells in images captured from different slides retrospectively selected from hospital records was designed and the concordance with results given by an expert pathologist was compared...
February 2019: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
Mauro Cives, Eleonora Pelle', Davide Quaresmini, Francesca Maria Rizzo, Marco Tucci, Franco Silvestris
<br>Neuroendocrine tumors (NETs) include a heterogeneous group of malignancies arising in the diffuse neuroendocrine system and characterized by indolent growth. Complex interactions take place among the cellular components of the microenvironment of these tumors, and the recognition of the molecular mediators of their interplay and cross-talk is crucial to discover novel therapeutic targets. NET cells overexpress a plethora of proangiogenic molecules including VEGF, PDGF, FGF, semaphorins and angiopoietins, that promote both recruitment and proliferation of endothelial cell precursors, thus resulting among the most vascularized cancers with a microvessel density 10-fold higher then epithelial tumors...
January 30, 2019: Neuroendocrinology
Brendan M Finnerty, Maureen Moore, Akanksha Verma, Anna Aronova, Shixia Huang, Dean P Edwards, Zhengming Chen, Marco Seandel, Theresa Scognamiglio, Nancy Du, Olivier Elemento, Rasa Zarnegar, Irene M Min, Thomas J Fahey
Loss of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) expression by CpG promoter hypermethylation is associated with metastasis in gastroenteropancreatic neuroendocrine tumors; however, the mechanism of how UCHL1 loss contributes to metastatic potential remains unclear. In this study, we first confirmed that loss of UCHL1 expression on immunohistochemistry was significantly associated with metastatic tumors in a translational pancreatic neuroendocrine tumor (PNET) cohort, with a sensitivity and specificity of 78% and 89%, respectively...
January 1, 2019: Endocrine-related Cancer
Taymeyah Al-Toubah, Stefano Partelli, Mauro Cives, Valentina Andreasi, Franco Silvestris, Massimo Falconi, Daniel Anaya Saenz, Jonathan Strosberg
New systemic treatments have improved the therapeutic landscape for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). While drugs such as everolimus, sunitinib, temozolomide, and 177Lutetium-dotatate are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression. Surgical resection, radiofrequency ablation (RFA), hepatic arterial embolization (HAE), or radiation, can control discrete sites of progression, allowing patients to continue their existing therapy, and sparing them toxicities of a new systemic treatment...
January 1, 2019: Endocrine-related Cancer
Andrea Mafficini, Aldo Scarpa
Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) are heterogeneous regarding site of origin, biological behavior and malignant potential. There has been a rapid increase in data publication over the last 10 years, mainly driven by high-throughput studies on pancreatic and small intestinal NETs. This review summarizes the present knowledge on genetic and epigenetic alterations. We integrated the available information from each compartment to give a pathway-based overview. This provided a summary of the critical alterations sustaining neoplastic cells...
January 17, 2019: Endocrine Reviews
Hallbera Gudmundsdottir, Páll Helgi Möller, Jon Gunnlaugur Jonasson, Einar S Björnsson
OBJECTIVE: To determine the incidence, distribution, and prognosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) over the last 30 years and analyze changes over time. METHODS: All patients diagnosed with GEP-NETs in Iceland from 1985 to 2014 were identified through the Icelandic Cancer Registry and pathology laboratory records. Relevant clinical information was obtained from medical records. In order to assess trends, the study period was divided into two periods, 1985-1999 and 2000-2014...
January 13, 2019: Scandinavian Journal of Gastroenterology
Katharine E H Thomas, Brianne A Voros, J Philip Boudreaux, Ramcharan Thiagarajan, Eugene A Woltering, Robert A Ramirez
Poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEPNECs) are a rare neoplasm with a bleak prognosis. Currently there are little prospective data available for optimal treatment. This review discusses the current available regimens and the future direction for the treatment of GEPNECs. Treatment plans for GEPNECs are often adapted from those devised for small cell lung cancer; however, differences in these malignancies exist, and GEPNECs require their own treatment paradigms. As such, current first-line treatment for GEPNECs is platinum-based chemotherapy with etoposide...
January 11, 2019: Oncologist
Florian Bösch, Katharina Brüwer, Annelore Altendorf-Hofmann, Christoph J Auernhammer, Christine Spitzweg, C Benedikt Westphalen, Stefan Boeck, Gabriele Schubert-Fritschle, Jens Werner, Volker Heinemann, Thomas Kirchner, Martin Angele, Thomas Knösel
Cancer immunotherapy has evolved major breakthroughs in the last years. The cell surface receptor programmed death-1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1) have been detected in various cancer types. However the analysis in gastroenteropancreatic neoplasia (GEP-NENs) is limited. Therefore, the aim of this study was to characterize GEP-NENs with regard to PD-1/PD-L1 pathway and tumor infiltrating lymphocytes (TILs). On protein level we examined TILs, PD-1 and PD-L1 expression in tumor tissue of 244 GEP-NENs using immunohistochemistry...
January 1, 2019: Endocrine-related Cancer
Ying-Hsia Chu, Heather Hardin, Jens Eickhoff, Ricardo V Lloyd
Recent studies suggest onco-regulatory roles for two long non-coding RNAs (lncRNAs), MALAT1 and HOTAIR, in various malignancies; however, these lncRNAs have not been previously examined in neuroendocrine neoplasms (NENs) of gastroenteropancreatic origins (GEP-NENs). In this study, we evaluated the expressions and prognostic significance of MALAT1 and HOTAIR in 83 cases of GEP-NENs (60 grade 1, 17 grade 2, and 6 grade 3 tumors) diagnosed during the years 2005-2017. Expression levels of MALAT1 and HOTAIR were digitally quantitated in assembled tissue microarray slides labeled by chromogenic in situ hybridization (ISH) using InForm 1...
January 2, 2019: Endocrine Pathology
Abdullah Sakin, Makbule Tambas, Saban Secmeler, Orçun Can, Serdar Arici, Nurgul Yasar, Caglayan Geredeli, Cumhur Demir, Sener Cihan
Background: Neuroendocrine tumors are a heterogeneous group of tumors that can originate from all of the neuroendocrine cells in the body, mostly from the gastrointestinal tract. In addition to early diagnosis, streaming patients into appropriate prognostic groups is an important component of treatment. In this study, we examined the factors that affect survival in patients we followed in our center between 2000-2016. Methods: The demographic data, clinical and pathological features of patients were obtained from their medical files...
December 25, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"